News
Diabetic Kidney Disease Therapies Keep on FLOWing
- Author:
- Kevin Fernando, MBChB, MSc
The FLOW study has elevated semaglutide to a new pillar of care for the management of diabetic kidney disease.
Opinion
Once-Weekly Insulin: A Game-Changer for Primary Care
- Author:
- Kevin Fernando, MBChB, MSc
“Game-changer” is an overused term, but from the perspective of primary care, it applies to once-weekly insulin.
Opinion
Debate: Is lasting remission of type 2 diabetes feasible in the real-world setting?
- Author:
- Kevin Fernando, MBChB, MSc
Dr. Taylor suggested that we not label these individuals who have lost significant weight as having prediabetes. Instead “postdiabetes” should be...
Opinion
Beyond A1c: Implementing the new ESC 2023 guidelines
- Author:
- Kevin Fernando, MBChB, MSc
Controversially, the updated ESC guidance suggests the use of metformin only in patients with type 2 diabetes and atherosclerotic cardiovascular...
Opinion
Oral GLP-1 agonists could be game changers for obesity
- Author:
- Kevin Fernando, MBChB, MSc
I hope that future developments bring the class to an even wider demographic and perhaps reduce some of the global inequities in managing type 2...
Opinion
Tirzepatide: Therapeutic titan or costly cure?
- Author:
- Kevin Fernando, MBChB, MSc
Positioning tirzepatide as the first injectable of choice after oral treatment escalation with metformin and an SGLT2 inhibitor may remain an...